Clinical Trial Update: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of ruxolitinib cream in children and adolescents aged 6 to <18 with moderate atopic dermatitis an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Ruxolitinib Cream (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Atopic Dermatitis | Phase 3 | Status: RECRUITING